Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

UCL and Syncona have both returned for Freeline's series B round, which will spur clinical development of the spinout's gene therapy for haemophilia B.

Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.

Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.

GV is reportedly leading a funding round for Lime, a bike-sharing platform also backed by NGP Capital and the Stanford-StartX fund.

Cambridge Innovation Capital has returned after backing CMR Surgical's two-tranche $46m series A round in 2016 and 2017.

UC's Office of the Chief Investment Officer has backed a new immuno-oncology startup that has licensed 17 assets from Pfizer.

UC Investment Office, an existing Constellation backer, has returned to contribute to a $100m round that took its total equity funding to $229m.

Reflexion Medical, partially based on research at UChicago, secured the Rise Fund as lead investor, with Pfizer and Johnson & Johnson returning.